Study design and rationale of "Synergistic Effect of Combination Therapy with Cilostazol and ProbUcol on Plaque Stabilization and Lesion REgression (SECURE)" study: A double-blind randomised controlled multicenter clinical trial

Trials

Volumn 12, Issue , 2011, Pages

  Ko, Young Guk ^a   Kim, Byeong Keuk ^a,h   Lee, Byoung K ^b   Kang, Woong C ^c   Choi, Seung H ^d   Kim, Sang W ^e   Lee, Jong H ^f   Lee, Myoungsook ^g   Honda, Yasuhiro ^h   Fitzerald, Peter J ^h   Shim, Won Heum ^a  

^a Yonsei University Health System   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Gachon University College of Medicine   (South Korea)

^d Sungkyunkwan University   (South Korea)

^e Chung Ang University College of Medicine   (South Korea)

^f Yonsei University   (South Korea)

^g Sungshin Women's University   (South Korea)

^h STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHOLESTEROL; CILOSTAZOL; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PROBUCOL; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR; ZOTAROLIMUS; ANTITHROMBOCYTIC AGENT; AUTACOID; BIOLOGICAL MARKER; HYPOCHOLESTEROLEMIC AGENT; LIPID; TETRAZOLE DERIVATIVE;

ADULT; ARTICLE; ATHEROSCLEROTIC PLAQUE; COMBINATION CHEMOTHERAPY; CORONARY ARTERY ATHEROSCLEROSIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG ELUTING STENT; DRUG POTENTIATION; FEMALE; HISTOLOGY; HUMAN; INFLAMMATION; INTRAVASCULAR ULTRASOUND; LIPID BLOOD LEVEL; LIPID COMPOSITION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; STUDY DESIGN; TREATMENT OUTCOME; ANGIOCARDIOGRAPHY; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE COURSE; DRUG COMBINATION; ENDOSCOPIC ECHOGRAPHY; INSTRUMENTATION; METHODOLOGY; SOUTH KOREA; STENT; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, BALLOON, CORONARY; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFLAMMATION MEDIATORS; LIPIDS; MALE; PLATELET AGGREGATION INHIBITORS; PROBUCOL; REPUBLIC OF KOREA; RESEARCH DESIGN; STENTS; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 78651244743     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-12-10     Document Type: Article

References (35)

1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, . Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2005, 366:1267-1278. 10.1016/S0140-6736(05)67394-1, 16214597, Cholesterol Treatment Trialists' (CTT) Collaborators.
2. Yamashita S, Matsuzawa Y. Where are we with probucol: a new life for an old drug?. Atherosclerosis 2009, 207:16-23. 10.1016/j.atherosclerosis.2009.04.002, 19457483.
3. Sasahara M, Raines EW, Chait A, Carew TE, Steinberg D, Wahl PW, Ross R. Inhibition of hypercholesterolemia induced atherosclerosis in the nonhuman primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation?. J Clin Invest 1994, 94:155-164. 10.1172/JCI117301, 296293, 8040256.
4. Franceschini G, Sirtori M, Vaccarino V, Gianfranceschi G, Rezzonico L, Chiesa G, Sirtori CR. Mechanisms of HDL reduction after probucol. Changes in HDL subfractions and increased reverse cholesteryl ester transfer. Arteriosclerosis 1989, 9:462-469.
5. Ishigami M, Yamashita S, Sakai N, Hirano K, Arai T, Maruyama T, Takami S, Koyama M, Kameda-Takemura K, Matsuzawa Y. High-density lipoproteins from probucol-treated patients have increased capacity to promote cholesterol efflux frommouse peritoneal macrophages loaded with acetylated low-density lipoproteins. Eur J Clin Invest 1997, 27:285-292. 10.1046/j.1365-2362.1997.1040657.x, 9134376.
6. Hirano K, Ikegami C, Tsujii K, Zhang Z, Matsuura F, Nakagawa-Toyama Y, Koseki M, Masuda D, Maruyama T, Shimomura I, Ueda Y, Yamashita S. Probucol enhances the expression of human hepatic scavenger receptor class B type I, possibly through a species-specific mechanism. Arterioscler Thromb Vasc Biol 2005, 25:2422-2427. 10.1161/01.ATV.0000185834.98941.3d, 16151015.
7. Miida T, Seino U, Miyazaki O, Hanyu O, Hirayama S, Saito T, Ishikawa Y, Akamatsu S, Nakano T, Nakajima K, Okazaki M, Okada M. Probucol markedly reduces HDL phospholipids and elevated prebeta1-HDL without delayed conversion into alpha-migrating HDL: Putative role of angiopoietin-like protein 3 in probucolinduced HDL remodeling. Atherosclerosis 2008, 200:329-335. 10.1016/j.atherosclerosis.2007.12.031, 18279878.
8. Fruebis J, Gonzalez V, Silvestre M, Palinski W. Effect of probucol treatment on gene expression of VCAM-1, MCP-1, and M-CSF in the aortic wall of LDL receptor-deficient rabbits during early atherogenesis. Arterioscler Thromb Vasc Biol 1997, 17:1289-1302.
9. Lau AK, Leichtweis SB, Hume P, Mashima R, Hou JY, Chaufour X, Wilkinson B, Hunt NH, Celermajer DS, Stocker R. Probucol promotes functional reendothelialization in balloon-injured rabbit aortas. Circulation 2003, 107:2031-2036. 10.1161/01.CIR.0000062682.40051.43, 12681995.
10. Weintraub WS. The vascular effects of cilostazol. Can J Cardiol 2006, 22(Suppl B):56B-60B. 2780845, 16498513.
11. Nakamura T, Houchi H, Minami A, Sakamoto S, Tsuchiya K, Niwa Y, Minakuchi K, Nakaya Y. Endothelium-dependent relaxation by cilostazol, a phosphodiesteras III inhibitor, on rat thoracic aorta. Life Sci 2001, 69:1709-1715. 10.1016/S0024-3205(01)01258-9, 11665832.
12. Kim KY, Shin HK, Choi JM, Hong KW. Inhibition of lipopolysaccharide-induced apoptosis by cilostazol in human umbilical vein endothelial cells. J Pharmacol Exp Ther 2002, 300:709-715. 10.1124/jpet.300.2.709, 11805237.
13. Okutsu R, Yoshikawa T, Nagasawa M, Hirose Y, Takase H, Mitani K, Okada K, Miyakoda G, Yabuuchi Y. Cilostazol inhibits modified low-density lipoprotein uptake and foam cell formation in mouse peritoneal macrophages. Atherosclerosis 2009, 204:405-411. 10.1016/j.atherosclerosis.2008.10.042, 19108834.
14. Ishizaka N, Taguchi J, Kimura Y, Ikari Y, Aizawa T, Togo M, Miki K, Kurokawa K, Ohno M. Effects of a single local administration of cilostazol on neointimal formation in balloon-injured rat carotid artery. Atherosclerosis 1999, 142:41-46. 10.1016/S0021-9150(98)00147-6, 9920504.
15. Tani T, Uehara K, Sudo T, Marukawa K, Yasuda Y, Kimura Y. Cilostazol, a selective type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats. Atherosclerosis 2000, 152:299-305. 10.1016/S0021-9150(99)00480-3, 10998457.
16. Elam MB, Heckman J, Crouse JR, Hunninghake DB, Herd JA, Davidson M, Gordon IL, Bortey EB, Forbes WP. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol 1998, 18:1942-1947.
17. Sekiya M, Funada J, Watanabe K, Miyagawa M, Akutsu H. Effects of probucol and cilostazol alone and in combination on the frequency of poststenting restenosis. Am J Cardiol 1998, 82:144-147. 10.1016/S0002-9149(98)00323-3, 9678282.
18. Yoshikawa T, Mitani K, Kotosai K, Nozako M, Miyakoda G, Yabuuchi Y. Antiatherogenic effects of cilostazol and probucol alone, and in combination in low density lipoprotein receptor-deficient mice fed with a high fat diet. Horm Metab Res 2008, 40:473-478. 10.1055/s-2008-1065348, 18404599.
19. Park SY, Lee JH, Shin HK, Kim CD, Lee WS, Rhim BY, Shin YW, Hong KW. Synergistic efficacy of concurrent treatment with cilostazol and probucol on the suppression of reactive oxygen species and inflammatory markers in cultured human coronary artery endothelial cells. Korean J Physiol Pharmacol 2008, 12:165-170. 10.4196/kjpp.2008.12.4.165, 2788631, 19967051.
20. Nair A, Kuban BD, Tuzcu EM, Schoenhagen P, Nissen SE, Vince DG. Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation 2002, 106:2200-2206. 10.1161/01.CIR.0000035654.18341.5E, 12390948.
21. Nasu K, Tsuchikane E, Katoh O, Vince DG, Virmani R, Surmely JF, Murata A, Takeda Y, Ito T, Ehara M, Matsubara T, Terashima M, Suzuki T. Accuracy of in vivo coronary plaque morphology assessment: a validation study of in vivo virtual histology compared with in vitro histopathology. J Am Coll Cardiol 2006, 47:2405-2412. 10.1016/j.jacc.2006.02.044, 16781367.
22. Yokoyama M, Komiyama N, Courtney BK, Nakayama T, Namikawa S, Kuriyama N, Koizumi T, Nameki M, Fitzgerald PJ, Komuro I. Plasma low-density lipoprotein reduction and structural effects on coronary atherosclerotic plaques by atorvastatin as clinically assessed with intravascular ultrasound radio-frequency signal analysis: A randomized prospective study. the effects of drugs on stabilization of coronary atherosclerotic plaques. Am Heart J 2005, 150:287.e1-287.e7.
23. Nasu K, Tsuchikane E, Katoh O, Tanaka N, Kimura M, Ehara M, Kinoshita Y, Matsubara T, Matsuo H, Asakura K, Asakura Y, Terashima M, Takayama T, Honye J, Hirayama A, Saito S, Suzuki T. Effect of fluvastatin on progression of coronary atherosclerotic plaque evaluated by virtual histology intravascular ultrasound. JACC Cardiovasc Interv 2009, 2:689-696. 10.1016/j.jcin.2009.04.016, 19628194.
24. Serruys PW, García-García HM, Buszman P, Erne P, Verheye S, Aschermann M, Duckers H, Bleie O, Dudek D, Bøtker HE, von Birgelen C, D'Amico D, Hutchinson T, Zambanini A, Mastik F, van Es GA, van der Steen AF, Vince DG, Ganz P, Hamm CW, Wijns W, Zalewski A, . Integrated Biomarker and Imaging Study-2 Investigators Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008, 118:1172-1182. 10.1161/CIRCULATIONAHA.108.771899, 18765397, Integrated Biomarker and Imaging Study-2 Investigators.
25. Hong MK, Park DW, Lee CW, Lee SW, Kim YH, Kang DH, Song JK, Kim JJ, Park SW, Park SJ. Effects of statin treatments on coronary plaques assessed by volumetric virtual histology intravascular ultrasound analysis. JACC Cardiovasc Interv 2009, 2:679-688. 10.1016/j.jcin.2009.03.015, 19628193.
26. Jang Y, Paik JK, Hyun YJ, Chae JS, Kim JY, Choi JR, Lee SH, Shin DJ, Ordovas JM, Lee JH. The apolipoprotein A5-1131T>C promoter polymorphism in Koreans: association with plasma APOA5 and serum triglyceride concentrations, LDL particle size and coronary artery disease. Clin Chim Acta 2009, 402:83-87. 10.1016/j.cca.2008.12.024, 19159622.
27. Patsch W, Brown SA, Morrisett JD, Gotto AM, Patsch JR. A dual-precipitation method evaluated for measurement of cholesterol in high-density lipoprotein subfractions HDL2 and HDL3 in human plasma. Clin Chem 1989, 2:265-270.
28. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM, . ASTEROID Investigators Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID Trial. JAMA 2006, 295:1556-1565. 10.1001/jama.295.13.jpc60002, 16533939, ASTEROID Investigators.
29. Tardif JC, Grégoire J, L'Allier PL, Ibrahim R, Anderson TJ, Reeves F, Title LM, Schampaert E, LeMay M, Lespérance J, Scott R, Guertin MC, Brennan ML, Hazen SL, . Bertrand OF; CART-2 Investigators Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial. Atherosclerosis 2008, 197:480-486. 10.1016/j.atherosclerosis.2006.11.039, 17214993, Bertrand OF; CART-2 Investigators.
30. Sawayama Y, Shimizu C, Maeda N, Tatsukawa M, Kinukawa N, Koyanagi S, Kashiwagi S, Hayashi J. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol 2002, 39:610-616. 10.1016/S0735-1097(01)01783-1, 11849859.
31. Yamashita S, Bujo H, Arai H, Harada-Shiba M, Matsui S, Fukushima M, Saito Y, Kita T, Matsuzawa Y. Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan. J Atheroscler Thromb 2008, 15:292-303.
32. Tardif JC, Cöté G, Lespérance J, Bourassa M, Lambert J, Doucet S, Bilodeau L, Nattel S, de Guise P. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N Engl J Med 1997, 337:365-372. 10.1056/NEJM199708073370601, 9241125.
33. Superko HR, Gadesam RR. Is it LDL particle size or number that correlates with risk for cardiovascular disease?. Curr Atheroscler Rep 2008, 10:377-385. 10.1007/s11883-008-0059-2, 18706278.
34. Colvin PL, Parks JS. Metabolism of high density lipoprotein subfractions. Curr Opin Lipidol 1999, 10:309-314. 10.1097/00041433-199908000-00004, 10482133.
35. Tall AR, Yvan-Charvet L, Wang N. The Failure of Torcetrapib: was it the Molecule or the Mechanism?. Arterioscler Thromb Vasc Biol 2007, 27:257-260. 10.1161/01.ATV.0000256728.60226.77, 17229967.